guidelines
People and collections that write or publish treatment guidelines. 18 records carry it: 14 people, 4 collections.
Related tags
By kind
18 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Alexander J. Stratigos Professor of Dermatology, National and Kapodistrian University of Athens, Andreas Sygros Hospital · National and Kapodistrian University of Athens, School of Medicine Athens dermatologist who led the trial showing that cemiplimab works in advanced basal cell carcinoma after Hedgehog inhibitors have failed, and who co-authors the European skin cancer guidelines. | Locally advanced and metastatic basal cell carcinoma, Advanced cutaneous squamous cell carcinoma, Skin cancer | none | skin, immunotherapy | ||
ASCO clinical practice guidelines American Society of Clinical Oncology ASCO guidelines are the American oncology society's guidelines, strongest on supportive care, survivorship, biomarker testing and resource-stratified recommendations for lower-income settings, complementing NCCN's algorithms. | none | none | none | ||
Barbara Eichhorst Professor of Medicine and Head of the CLL Outpatient Clinic, University Hospital Cologne; Secretary, German CLL Study Group · Uniklinik Köln (CIO) Led CLL13 (GAIA), showing venetoclax-based fixed-duration therapy beats chemoimmunotherapy in fit CLL patients. | Chronic lymphocytic leukaemia | none | cll, venetoclax | ||
Bryan R. Haugen Professor of Medicine and Head of Endocrinology, University of Colorado · University of Colorado Cancer Center Colorado endocrinologist who chaired the 2015 American Thyroid Association guidelines, the reference for how thyroid nodules and differentiated thyroid cancer are diagnosed and treated. | Papillary thyroid cancer, Follicular thyroid cancer, Thyroid cancer | none | thyroid | ||
CSCO guidelines (China) Chinese Society of Clinical Oncology CSCO guidelines are China's national oncology guidelines, covering about 30 cancers and updated annually. They grade each recommendation by both evidence level and affordability under China's reimbursement list, and they cover Chinese-developed drugs (PD-1 inhibitors, ADCs) and cancers common in China (nasopharyngeal, oesophageal, liver, gastric) years before Western guidelines. | none | none | none | ||
Eric Van Cutsem Professor of Medicine and Head of Digestive Oncology, University Hospitals Leuven · UZ Leuven / Leuven Cancer Institute Led CRYSTAL, which established cetuximab in RAS wild-type colorectal cancer, and has shaped ESMO's GI guidelines for two decades. | Colorectal cancer, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma | none | colorectal, esmo | ||
Florian Lordick Director, University Cancer Center Leipzig; Professor of Oncology, University of Leipzig · Leipzig University Hospital / University Cancer Center Leipzig (UCCL) German GI oncologist who leads ESMO's gastric cancer guidelines and pivotal perioperative trials. | Gastric & gastro-oesophageal junction cancer, Oesophageal cancer | none | gastric, esmo | ||
Hartmut Döhner Medical Director, Department of Internal Medicine III, Ulm University Hospital · Ulm University Hospital / Comprehensive Cancer Center Ulm Leads the European LeukemiaNet classification that defines how AML is diagnosed and risk-stratified worldwide. | Acute myeloid leukaemia | none | aml, classification | ||
Hedy L. Kindler Professor of Medicine and Director of Gastrointestinal Oncology and Mesothelioma Programs, University of Chicago · University of Chicago Medicine Comprehensive Cancer Center Senior investigator of POLO and a leader in mesothelioma trials, including the ASCO guidelines for the disease. | Pancreatic ductal adenocarcinoma, Mesothelioma | none | pancreatic, mesothelioma | ||
Japanese oncology guidelines (JSMO, JSCO and organ societies) JSMO / JSCO The JSMO and JSCO guidelines are Japan's oncology guidelines, especially strong for gastric, oesophageal, liver and biliary cancers where Japanese trials set global standards (D2 gastrectomy, S-1, endoscopic resection), and for Japan's own approvals through PMDA. | none | none | none | ||
Keith C. Bible Medical oncologist, Mayo Clinic · Mayo Clinic Mayo Clinic oncologist who chaired the American Thyroid Association guidelines for anaplastic thyroid cancer, one of the fastest-growing human cancers. | Anaplastic thyroid cancer, Thyroid cancer | none | thyroid | ||
Laurence Albiges Head of the Department of Medical Oncology, Gustave Roussy · Gustave Roussy French kidney cancer specialist who co-led CheckMate 214 and the belzutifan trials. | Renal cell carcinoma | none | rcc, hif2a | ||
Miguel A. Sanz Haematologist, Hospital Universitari i Politècnic La Fe, Valencia · Hospital Universitari i Politècnic La Fe Spanish haematologist who led the PETHEMA trials that tailored acute promyelocytic leukaemia treatment to relapse risk, and who chaired the European LeukemiaNet recommendations for the disease. | Acute promyelocytic leukaemia, Acute myeloid leukaemia | none | leukaemia | ||
Nadia Harbeck Head of the Breast Center, LMU University Hospital Munich; Chair, West German Study Group · LMU Klinikum München German breast oncologist whose ADAPT trials use biology to decide who can have less chemotherapy. | HR-positive / HER2-negative breast cancer, HER2-positive breast cancer | none | breast, de-escalation | ||
NICE cancer guidance and technology appraisals (UK) National Institute for Health and Care Excellence NICE decides which cancer treatments the NHS pays for, publishing for each drug an appraisal of cost per quality-adjusted life year against a threshold of about £20,000 to £30,000, plus clinical guidelines. Because the manufacturer models and committee reasoning are public, its decisions serve as an independent view of a drug's value that often diverges from FDA and EMA licensing. | none | none | none | ||
Nicoletta Colombo Director of Gynaecologic Oncology, European Institute of Oncology (IEO), Milan; Professor, University of Milan-Bicocca · IEO (European Institute of Oncology) Led KEYNOTE-826, which made pembrolizumab plus chemotherapy the first-line standard for recurrent or metastatic cervical cancer. | Cervical cancer, Ovarian cancer | none | cervical, immunotherapy | ||
Silke Gillessen Medical and Scientific Director, Oncology Institute of Southern Switzerland (IOSI), Bellinzona · Oncology Institute of Southern Switzerland (IOSI) Founder and chair of the APCCC consensus conference that guides advanced prostate cancer management worldwide. | Prostate cancer | none | prostate, switzerland | ||
William G. Wierda Professor and Section Chief of CLL, Department of Leukemia, MD Anderson Cancer Center · MD Anderson Cancer Center Led CAPTIVATE, which established fixed-duration ibrutinib plus venetoclax as a first-line option for CLL. | Chronic lymphocytic leukaemia | none | cll, fixed-duration |
